Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee’s assessment of cohort 1

Gothenburg, April 10, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company’s commercially available iTANK platform, today announced that the Data Safety and Monitoring Board (DSMB) has completed its first assessment of the ongoing Phase I/IIa CARMA clinical trial with the CAR T-cell therapy ELC-301 for the treatment of B-cell lymphoma. The DMSB recommended that the study continue as planned.

The dose-escalation study, conducted in collaboration with Uppsala University as sponsor, previously reported a complete response (no detectable tumor) in the first treated patient at the initial follow-up one month after completing treatment, with no serious adverse events observed. Two additional patients have since been treated at the lowest dose level in the first dosing group (cohort 1). Elicera intends to report preliminary results from the study as each dosing cohort is completed. Preliminary efficacy data from the first cohort is expected to be presented at the 7th Swedish Cancer Research Meeting in Malmö on May 22.

Following the DSMB’s recommendation to proceed, treatment of patients in the second cohort at next dose level can now begin.